First Half 2026 Recap: Nephrology

The first half of 2026 marked a transformative period in nephrology, with landmark regulatory approvals, evolving clinical practice guidelines, and pivotal phase 3 trial results accelerating a shift toward precision medicine and disease modification. Across chronic kidney disease (CKD), IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and other glomerular diseases, the US Food and Drug Administration (FDA) advanced multiple therapies through priority reviews and approvals while investigators reported encouraging long-term data from late-stage clinical trials.